Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Constant Therapeutics Announces Start of Phase 2 Trial of Peptide Drug TXA127 for COVID-19

americanpharmaceuticalreviewAugust 06, 2020

Tag: TXA127 , COVID-19 , Constant Therapeutics

PharmaSources Customer Service